A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)., PMID:40465056
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis., PMID:40402264
Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis., PMID:40367683
Interventions for idiopathic steroid-resistant nephrotic syndrome in children., PMID:40337980
Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database., PMID:40235349
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies., PMID:40225374
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis., PMID:40214505
The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function., PMID:40180777
Reconstitution of CXCR3+ CCR6+ Th17.1-Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis., PMID:40164501
Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report., PMID:40154217
Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review., PMID:40145095
Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura., PMID:40134425
Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model., PMID:40130187
Effective treatment of immune mediated peripheral neuropathy with Ofatumumab - A case report., PMID:40121773
Immune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study., PMID:40107181
Effect of Treatment on Steroidome in Women with Multiple Sclerosis., PMID:40076462
[Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis]., PMID:40047834
Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis., PMID:39974306
Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis., PMID:39933126
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis., PMID:39917326
The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system., PMID:39917308
Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series., PMID:39845958
Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study., PMID:39835156
Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice., PMID:39834277
Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis., PMID:39833702
Ofatumumab for treating autoimmune nodopathy., PMID:39800963
Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy., PMID:39787234
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells., PMID:39774793
Ofatumumab-exposed breastfeeding in multiple sclerosis patients., PMID:39757874
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches., PMID:39742715
Case report: paraneoplastic cerebellar degeneration associated with anti-Yo antibody successfully treated with ofatumumab., PMID:39737186
Ofatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection., PMID:39729629
Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials., PMID:39711787
Ofatumumab for multiple sclerosis with disability accumulation., PMID:39708694
Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy., PMID:39687682
The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series., PMID:39660186
Ofatumumab-associated colitis: A case report., PMID:39644146
Efficacy of ofatumumab combined with corticosteroids in the treatment of autoimmune encephalitis: a 6-month cohort study., PMID:39602016
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab., PMID:39582359
Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis., PMID:39575244
Impact of Continuous Ofatumumab Exposure During Pregnancy in Multiple Sclerosis., PMID:39524100
Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis., PMID:39515320
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children., PMID:39513526
Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis., PMID:39388747
Profiling the impact of anti-human CD20 monoclonal antibodies on lymphocyte B cell subsets and their precursors in the bone marrow and in lymphoid tissues in an immunocompromised mouse engrafted with human cells., PMID:39374887
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials., PMID:39307151
Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset., PMID:39299183
Ofatumumab treatment for severe refractory anti-NMDAR encephalitis: A case series., PMID:39277986
B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease., PMID:39259430
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis., PMID:39254048